Jingtai Holdings (02228) reaches over $400 million strategic cooperation for AI drug discovery with international renowned pharmaceutical company, focusing on oral new drugs targeting GPCR receptors.

Intelligence Finance APP News, Jintai Holdings (02228) announced that the company's board of directors happily announced a strategic partnership with an internationally renowned biopharmaceutical company. Both parties will jointly develop an innovative oral small molecule drug with "Best in-Class" potential targeting a GPCR (G protein-coupled receptor) target. This agreement is based on a rigorous and successful pilot phase, during which Jintai integrated quantum physics and AI algorithms to achieve a breakthrough hit rate, confirming the platform's ability to handle such complex metabolic targets.